Trial Profile
Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- 26 Feb 2019 Status changed to withdrawn prior to enrolment.
- 17 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 17 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2018.